[ad_1]
A ROCKY TREATMENT AGAINST ARTHRITIS EFFECTIVE ENOUGH COVID-19, STUDY
ZURICH (Reuters) – Actemra, a Roche drug originally targeted for arthritis, has shown some efficacy in treating COVID-19 in a study involving 303 patients, a study author said Thursday.
This anti-inflammatory drug, also called tocilizumab, has achieved an “important efficacy endpoint” in critically ill patients compared to patients who have not received treatments that involve modulating the immune system, according to initial data from the REMAP-CAP test.
Anthony Gordon, professor of anesthesia and intensive care at Imperial College London, however, said it is not yet known whether Actemra is saving patients and / or shortening the length of their hospital stay in the units. intensive care. Details on the study are expected to be published within a few weeks, but Anthony Gordon believes the initial results show Actemra is beneficial for patients.
Other treatments such as interferon beta 1a, interleukin-1 or even Kevzara, Sanofi’s arthritis drug, are part of the REMAP-CAP study, but their results have not yet been published. .
The study also concluded that lopinavir / ritonavir, AbbVie’s AIDS treatment, was not effective against COVID-19.
(John Miller; French version Claude Chendjou, edited by Jean-Michel Bélot)
.
[ad_2]
Source link
